


- retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. *Lancet Lond Engl.* 2019;394:1551–1559.
15. Fleck BW, Reynolds JD, Zhu Q, et al. Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW Trial. *Ophthalmol Retina.* 2022;6:628–637.
  16. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. *Am J Ophthalmol.* 2012;154:682–686.e2.
  17. Wu WC, Shih CP, Lien R, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. *Retina.* 2017;37:694–701.

## Pictures & Perspectives



### The Pseudo-Hypoplastic Myopic Optic Disc

A 7-year-old girl had 20/25 vision in the right eye (OD) (with correction) and 20/20 vision in the left eye (OS), with no afferent pupillary defect. Retinoscopy showed  $-4.75$  OD and plano OS. Retinal examination showed a small tilted right optic disc, with a temporal crescent of retinal pigment epithelium (RPE) and choroid pierced inferotemporally by a retinal vein (A). OCT showed a smaller right disc with a smaller neuroretinal rim and cup volume (B), but equal retinal nerve fiber layer (RNFL) (B) and ganglion cell thickness (bottom left). The thickened, retracted, temporal RNFL (C, asterisk) abutted the overhanging RPE (C, arrow). The myopic optic disc may simulate optic nerve hypoplasia both clinically and on OCT measurement (Magnified version of Fig A–C is available online at [www.aaojournal.org](http://www.aaojournal.org)).

MICHAEL C. BRODSKY, MD

Departments of Ophthalmology and Neurology, Mayo Clinic, Rochester, Minnesota

### Footnotes and Disclosures

Supported in part by Mayo Clinic, Rochester, Minnesota. The funding organization had no role in the design or conduct of this research.